These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25348528)

  • 41. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
    Louie A; Grasso C; Bahniuk N; Van Scoy B; Brown DL; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2646-54. PubMed ID: 20368395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
    Louie A; Liu W; Fikes S; Brown D; Drusano GL
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. L-658,310, a new injectable cephalosporin. II. In vitro and in vivo interactions between L-658,310 and various aminoglycosides or ciprofloxacin versus clinical isolates of Pseudomonas aeruginosa.
    Valiant ME; Gilfillan EC; Gadebusch HH; Pelak BA
    J Antibiot (Tokyo); 1989 May; 42(5):807-14. PubMed ID: 2498278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.
    Bergen PJ; Forrest A; Bulitta JB; Tsuji BT; Sidjabat HE; Paterson DL; Li J; Nation RL
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5134-42. PubMed ID: 21876058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations.
    Motos A; Avery LM; DeRonde KJ; Mullane EM; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2019 May; 53(5):698-702. PubMed ID: 30880231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.
    Liang W; Liu XF; Huang J; Zhu DM; Li J; Zhang J
    BMC Infect Dis; 2011 Apr; 11():109. PubMed ID: 21521536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
    Khalil H; Chen T; Riffon R; Wang R; Wang Z
    Antimicrob Agents Chemother; 2008 May; 52(5):1635-41. PubMed ID: 18285485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergistic effect of two antimicrobial peptides, Nisin and P10 with conventional antibiotics against extensively drug-resistant Acinetobacter baumannii and colistin-resistant Pseudomonas aeruginosa isolates.
    Jahangiri A; Neshani A; Mirhosseini SA; Ghazvini K; Zare H; Sedighian H
    Microb Pathog; 2021 Jan; 150():104700. PubMed ID: 33346078
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Copur B; Dosler S; Aktas Z; Basaran S; Simsek-Yavuz S; Cagatay A; Oncul O; Ozsut H; Eraksoy H
    Future Microbiol; 2022 Sep; 17():1027-1042. PubMed ID: 35796076
    [No Abstract]   [Full Text] [Related]  

  • 53. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
    Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
    Liu MT; Sheng MY; Zhang Y; Li Y
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1427-31. PubMed ID: 21756818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antimicrobial susceptibility of multidrug-resistant Pseudomonas aeruginosa isolated from drinking water and hospitalized patients in Jordan.
    Tarazi YH; Abu-Basha E; Ismail ZB; Al-Jawasreh SI
    Acta Trop; 2021 May; 217():105859. PubMed ID: 33582141
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
    Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia.
    García-Rodríguez JA; García Sánchez JE; Muñoz Bellido JL; García Sánchez E; García García MI
    J Chemother; 1991 Jun; 3(3):143-6. PubMed ID: 1919651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Gunderson BW; Ibrahim KH; Hovde LB; Fromm TL; Reed MD; Rotschafer JC
    Antimicrob Agents Chemother; 2003 Mar; 47(3):905-9. PubMed ID: 12604520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.